Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Antirheumatic Agents

Etoposide

Cytarabine

Rituximab

Melphalan

Etoposide phosphate

Carmustine

Antineoplastic Agents, Immunological

Immunologic Factors

Enzyme Inhibitors

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Antineoplastic Agents, Alkylating

Alkylating Agents

Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab

Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant

BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab

BEAM + Rituximab Followed by Stem Cell Transplant

(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.

Zevalin

Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant

Issa F. Khouri, MD

The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and rituximab alone in patients with lymphoma who receive a stem cell transplant.

The Study Drugs:

90Y Zevalin is designed to attach to lymphoma cells, and destroy the cells using a radiation particle that is attached to it.

111In Zevalin is like 90Y Zevalin, but the radioactive particle that is attached to it does not kill lymphoma cells. The radioactive particle makes the drug able to be seen inside your body. It is being used in this study to predict how fast the study drug will travel in the body and how long the drug stays in the body.

Carmustine, etoposide, cytarabine, and melphalan (BEAM) are designed to kill lymphoma cells by damaging the cells DNA.

Rituximab is designed to attach to lymphoma cells, which may cause them to die.

Study Groups 1 and 2:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the toss of a coin) to 1 of 2 groups. You will have an equal chance of being assigned to each group. Group 1 will receive 90Y Zevalin along with rituximab and BEAM therapy. Group 2 will receive rituximab and BEAM therapy. You and the study staff will know which group you are in.

Study Drug Administration:

If you are in Group 1, you will receive rituximab through a needle in your vein (over 4-5 hours) followed by 111In Zevalin by vein (over 15 minutes). A nuclear scan will be done within the following 40 to 48 hours to see how the drug is traveling through your body.

If intolerable side effects are not shown by the scans, you will receive rituximab (over 4-5 hours) and 90Y Zevalin (over 15 minutes) through a needle in your vein 7 days after the 111In Zevalin infusion.

You will begin BEAM chemotherapy 7 days after the second 90Y Zevalin infusion.

BEAM Chemotherapy:

Both groups will have 7 days of BEAM combination chemotherapy.

* On Day 1, you will receive carmustine through a needle in your vein over 1 hour.
* On Days 2-5 you will receive cytarabine by vein (over 1 hour) followed by etoposide (over 3 hours). Both infusions will be repeated every 12 hours on Days 2-5.
* On Day 6 you will be given melphalan by vein over 30 minutes.
* On Day 7 the stem cells that were collected earlier from you will be given back ("transplanted") through a catheter over 30-45 minutes.
* You will also receive rituximab by vein (over 5-7 hours) on Day 8.

You will receive rituximab (over 4-5 hours) 7 days after the stem cell transplant. You will receive G-CSF by injection once a day starting 7 days after the stem cell transplant until your blood counts return to a normal level. You should stay in the Houston area for about 2-4 weeks after the transplant.

Study Procedures:

At about 1 month after the transplant you will have x-rays, CT scans, and positron emission tomography (PET) scans. You will also have a bone marrow aspirate and biopsy to check the status of the disease.

Blood (about 1 tablespoon) will be drawn once a day while you are in the hospital to check your blood counts.

Blood tests (about 1-2 tablespoons), urine tests, bone marrow collections, and x-rays may be done as needed to track the effects of the transplant.

You will have transfusions of blood and platelets as needed.

Study Groups A and B:

About 1 month after the transplant, you will be randomly assigned (as in the toss of a coin) to 1 of 2 new groups (Group A and Group B). Group A will receive rituximab by vein over 5-7 hours, once every 3 months, starting 3 months after the stem cell transplant. You will receive rituximab for the first 18 months after the stem cell transplant. Group B will not receive rituximab. You will have an equal chance of being in each group.

Follow-up Visits:

You will return to the clinic every 6 months for 5 years to check the status of the disease. The following tests and procedures will be performed:

* Blood (about 1-2 tablespoons) and urine will be collected for routine tests.
* You will have a bone marrow biopsy to check the status of the disease.
* You will have a chest x-ray and a CT scan.
* You will have a PET scan.

Length of Study:

You may stay on study as long as you are benefitting. You will be taken off-study if the disease gets worse or intolerable side effects occur.

This is an investigational study. 90Y-Zevalin is approved by the FDA for relapsed and refractory lymphoma. Its use in this study is investigational. 111In Zevalin, Carmustine, etoposide, cytarabine, melphalan, and Rituximab are all FDA approved and commercially available. However, their use together in this study is also investigational. Up to 50 patients will be take part in this study. All will be enrolled at MD Anderson.

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas

Response evaluated using the standard criteria response for lymphoma through CT scan.

M.D. Anderson Cancer Center

Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab

Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.

Carmustine: 300 mg/m\^2 by vein.

Etoposide: 200 mg/m\^2 by vein every 12 hours.

Cytarabine: 200 mg/m\^2 by vein every 12 hours.

Melphalan: 140 mg/m\^2 by vein.

Rituximab: Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant: Injection of stem cells (Autologous SCT)

Group 1 - Zevalin + BEAM + Rituximab +Stem Cell Transplant

Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant

Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.

Carmustine: 300 mg/m\^2 by vein.

Etoposide: 200 mg/m\^2 by vein every 12 hours.

Cytarabine: 200 mg/m\^2 by vein every 12 hours.

Melphalan: 140 mg/m\^2 by vein.

Rituximab: Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant: Injection of stem cells (Autologous SCT)

Group 1 - Zevalin + BEAM + Stem Cell Transplant

BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab

Carmustine: 300 mg/m\^2 by vein.

Etoposide: 200 mg/m\^2 by vein every 12 hours.

Cytarabine: 200 mg/m\^2 by vein every 12 hours.

Melphalan: 140 mg/m\^2 by vein.

Rituximab: Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant: Injection of stem cells (Autologous SCT)

Group 2 - BEAM + Rituximab + Stem Cell Transplant

BEAM + Rituximab Followed by Stem Cell Transplant

Carmustine: 300 mg/m\^2 by vein.

Etoposide: 200 mg/m\^2 by vein every 12 hours.

Cytarabine: 200 mg/m\^2 by vein every 12 hours.

Melphalan: 140 mg/m\^2 by vein.

Rituximab: Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant: Injection of stem cells (Autologous SCT)

Spots Global Cancer Trial Database for ibritumomab

Every month we try and update this database with for ibritumomab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ibritumomab

Every month we try and update this database with for ibritumomab cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ibritumomab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.